Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Chimeric antigen receptor T (CAR-T) cell therapy has achieved extraordinary success in antitumor therapy, particularly in targeting hematologic malignancies, where it has led to significant long-term antitumor effects with higher target specificity. Chimeric antigen receptor T (CAR-T) therapy is the most rapidly developing and widely used branch of anti-cancer cellular immunotherapy. This latest technology is rapidly changing the landscape of hematologic malignancies and already accounts for more than half of the cellular therapies currently in development or on the market.
Creative Biogene leverages our advanced CAR-T cell development and manufacturing platform to provide customized CAR-T cell line development services. Our experienced scientists have extensive experience in CAR build design and can provide customers with comprehensive CAR-T cell development services.
Fig. 1 The application of CAR-T cell therapy in hematological malignancies. (Zhao, Z. et al, 2018)
Creative Biogene is committed to providing comprehensive solutions for the development of CAR-T cell therapies. We can help our clients support their projects during any of the following stages of development:
CAR is a key component of CAR-T cell therapy. Creative Biogene has extensive experience in CAR candidate development and build design. We offer a diverse range of scFv solutions, either by building CARs from customer antibody sequences or by generating entire constructs from mouse monoclonal antibodies or fully human single-chain variable antibody fragments (scFv) from existing libraries. In addition, our phage demonstration and scFv high-throughput screening platform can accelerate the development of CAR-T cell therapies.
Creative Biogene mimics the dual signaling effect of T cell activation by stimulating T cells in vitro with a combination of antibodies to CD3 and CD28. This is the most widely used method to perform T-cell activation and expansion, and can effectively support our customers' CAR-T cell development process.
The lentiviral vector used to transduce CAR into T cells is a key raw material in the production process of CAR-T cells. The capacity, cost and quality of lentiviral scale up production will directly affect the final therapeutic application of CAR-T products in all aspects. Creative Biogene provides comprehensive and efficient lentivirus packaging services, including materials for lentivirus packaging, reagents, serum-free HEK293 medium, plasmid DNA production services, etc.
After obtaining stable CAR-T cells, large-scale CAR-T cell expansion is required to obtain the dose needed to achieve the treatment. Creative Biogene's automated cell production equipment enables efficient, rapid production with high batch-to-batch consistency to accelerate customer project development.
Creative Biogene strictly adheres to GMP-grade quality management systems and release standards, and we perform quality control throughout the cell development process to ensure that we provide our clients with safe and stable CAR-T cells.
Creative Biogene provides a one-stop CAR-T cell manufacturing process. We provide a functionally closed manufacturing process during CAR-T cell development to reduce the risk of contamination of the product by the following development processes.
As a leading provider of CDMO services in the biopharmaceutical sector, Creative Biogene is committed to providing customized CAR-T cell development services to help our clients accelerate their development process. Please feel free to contact us if you have a need, and our experienced specialists will be happy to assist you.
Reference:
